English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 27 June 2016, 12:19 HKT/SGT

Source: China Everbright Ltd
China Everbright's RMB Mezzanine Fund invests in Neusoft Holdings
Strengthening Strategic Manoeuvres in the Healthcare Sector

HONG KONG, June 27, 2016 - (ACN Newswire) - China Everbright Limited's RMB Mezzanine Fund ("the Fund") announced that it has successfully completed its investment in Dalian Neusoft Holdings Co Ltd ("Neusoft Holdings"), a deal which is anticipated to help Neusoft Holdings make significant strategic manoeuvres in the healthcare sector. As mutually agreed, the Fund could convert part of its investment into equity in Neusoft Medical Systems Co Ltd ("Neusoft Medical") under certain conditions.

Neusoft Holdings and Neusoft Medical are led by Dr. Jiren Liu, the first person in China to receive a doctorate degree in computer applications. Since Neusoft's founding years in the early '90s, Dr. Liu and his team have developed a reputation for pursuing businesses that promote social progress and change. Following years of research and innovation, the team has built a group of quality companies involved in diverse industries including information services, medical equipment, health management and applied education. Among these is the publicly listed Neusoft Corporation, one of China's leading IT solutions and service providers which is known for its dominant market shares in numerous industries, especially its world-leading position as a software service provider for car navigation and aided driver safety systems.

Neusoft Medical is a quality supplier of medical equipment and services in China that has successfully developed CT, MRI and radiotherapy equipment using China's proprietary technology. Neusoft Medical's CT products have filled a particular void in China, making the country one of the world's few nations with CT manufacturing capability. These products are now exported to over 100 countries and territories around the world, benefiting more than 9,000 healthcare providers.

Founded in 2011, Neusoft Holdings' major investors include the management team of Neusoft Holdings, NEU Science & Technology Industry, and The People's Insurance Company of China. It mainly focuses on emerging hi-tech industries including education, internet services, IT, and healthcare. Neusoft Holdings also runs undergraduate institutions in Dalian, Chengdu and Foshan. In addition, it is a major investor in a range of companies including Neusoft Corporation, Neusoft Medical and Neusoft Xikang.

Mr. Shuang Chen, Executive Director & Chief Executive Officer of China Everbright Limited, said, "Dr. Jiren Liu is a highly respected entrepreneur in China. We are greatly honoured to work with Dr. Liu and his management team and play a part in Neusoft's phenomenal growth. In recent years, China Everbright Limited has stepped up its strategic planning efforts in the healthcare, elderly care, education and other sectors. With Neusoft's abundant resources and significant achievements in these sectors, we can see huge potential for cooperation by building on our complementary strengths."

About China Everbright Limited
China Everbright Limited ("CEL", stock code: 165.HK) was established at Hong Kong in 1997, CEL persistently pursues its "Macro Asset Management" strategy, with specific focuses on cross-border asset management and investment business. Over the past years, CEL manages series of private equity funds, venture capital funds, sector focus funds, mezzanine funds, hedge funds and principal investment as operated via an international management platform, and provides overseas investors with opportunities to explore and invest in companies with fast growing potential in Mainland China. On the other hand, CEL also seeks investment opportunities from overseas and provides diversified financial services for its clients in Mainland China. As of 31 December 2015, CEL's total fundraising scale reached over HK$49 billion, with a total of 31 funds.

China Everbright Limited, being a member of China Everbright Group, is the second largest shareholder of Everbright Securities (stock code: 601788.SH), a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK), the single largest shareholder of the Hong Kong-listed China Aircraft Leasing Group Holdings Limited (stock code: 1848.HK) and the second largest shareholder of the Singapore-listed Ying Li International Real Estate Limited (stock code: 5DM. SGX).

After the launch of "Shanghai-Hong Kong Stock Connect" on 10 April 2014, CEL becomes one of the first batch of specific stocks listed on The Stock Exchange of Hong Kong which can be directly traded by Mainland investors.

Through upholding the philosophy of "Making Wealth Simple", CEL leverages on its own substantial financial strength, as well as the position and influence of China Everbright Group and its affiliated companies in the financial industry in China, and has successfully built huge cross-border social and business networks in Hong Kong and the Mainland, and established a reputable image in the market.

For more information, please visit www.everbright165.com.

For enquiries, please contact:

Jackie Cheung
Tel: +852 2501 7901
Email: jcheung@golin.com

Max Lau
Tel: +852 2501 7905
Email: mlau@golin.com

Topic: Press release summary
Source: China Everbright Ltd

Sectors: Daily Finance, Daily News
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


China Everbright Ltd Related News
Apr 8, 2024 16:34 HKT/SGT
Apr 8, 2024 16:30 HKT/SGT
Aug 25, 2023 18:56 HKT/SGT
实现扭亏为盈 光大控股公布2023年中期业绩
Aug 25, 2023 18:55 HKT/SGT
實現扭虧為盈 光大控股公佈2023年中期業績
Aug 25, 2023 18:54 HKT/SGT
China Everbright Limited Announces 2023 Interim Results, Realises Turnaround of Loss to Profit
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575